Catabasis Pharmaceuticals | CATB

Catabasis Pharmaceuticals Profile

  • Sector: Health Technology
  • Industry: Biotechnology
  • Employees: 20

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Catabasis Pharmaceuticals in the news

Services We Offer

Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!

Machine Learning

Custom Scraper